Cristina Suárez

14.3k total citations · 4 hit papers
189 papers, 4.6k citations indexed

About

Cristina Suárez is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Cristina Suárez has authored 189 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Pulmonary and Respiratory Medicine, 69 papers in Molecular Biology and 60 papers in Oncology. Recurrent topics in Cristina Suárez's work include Renal cell carcinoma treatment (94 papers), Cancer Genomics and Diagnostics (48 papers) and Renal and related cancers (41 papers). Cristina Suárez is often cited by papers focused on Renal cell carcinoma treatment (94 papers), Cancer Genomics and Diagnostics (48 papers) and Renal and related cancers (41 papers). Cristina Suárez collaborates with scholars based in Spain, United States and United Kingdom. Cristina Suárez's co-authors include Fé Tubau, Thomas Powles, Robert J. Motzer, Carmen Peña, Francesc Gudiol, Toni K. Choueiri, Bernard Escudier, Joan Carles, Camillo Porta and Luis Martínez‐Martínez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Cristina Suárez

180 papers receiving 4.5k citations

Hit Papers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab M... 2021 2026 2022 2024 2021 2022 2024 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
    2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →
  2. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
    2022 177 citations Robert J. Motzer, Mauricio Burotto et al. profile →
  3. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2024 96 citations Laurence Albigès, Axel Bex et al. Annals of Oncology profile →
  4. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    2023 89 citations Toni K. Choueiri, Laurence Albigès et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cristina Suárez Spain 37 2.1k 1.6k 1.5k 923 741 189 4.6k
David Baldwin United Kingdom 40 5.0k 2.4× 734 0.5× 1.7k 1.2× 366 0.4× 547 0.7× 229 7.4k
Antonello Di Paolo Italy 34 477 0.2× 1.1k 0.7× 1.4k 0.9× 406 0.4× 295 0.4× 141 3.6k
Sunil Krishnan United States 55 2.9k 1.4× 1.8k 1.1× 3.7k 2.5× 1.3k 1.4× 2.1k 2.8× 197 9.1k
Jean‐Paul Sculier Belgium 44 4.7k 2.2× 1.5k 1.0× 4.3k 2.9× 619 0.7× 648 0.9× 228 8.0k
Judith E. Karp United States 66 879 0.4× 6.3k 3.9× 4.6k 3.1× 1.4k 1.5× 299 0.4× 275 14.2k
Christopher J. Burns Australia 34 306 0.1× 2.0k 1.3× 955 0.7× 333 0.4× 276 0.4× 128 4.3k
Jos G. W. Kosterink Netherlands 40 576 0.3× 761 0.5× 1.2k 0.8× 138 0.1× 411 0.6× 146 5.2k
Kyong Hwa Park South Korea 31 729 0.4× 1.2k 0.8× 1.2k 0.8× 685 0.7× 651 0.9× 219 3.9k
David J. Kuter United States 50 1.3k 0.6× 1.3k 0.8× 1.0k 0.7× 94 0.1× 947 1.3× 214 10.4k
Dorothea Nagel Germany 41 568 0.3× 1.2k 0.8× 1.2k 0.8× 974 1.1× 605 0.8× 86 3.9k

Countries citing papers authored by Cristina Suárez

Since Specialization
Citations

This map shows the geographic impact of Cristina Suárez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Suárez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Suárez more than expected).

Fields of papers citing papers by Cristina Suárez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristina Suárez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Suárez. The network helps show where Cristina Suárez may publish in the future.

Co-authorship network of co-authors of Cristina Suárez

This figure shows the co-authorship network connecting the top 25 collaborators of Cristina Suárez. A scholar is included among the top collaborators of Cristina Suárez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristina Suárez. Cristina Suárez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).
2.
Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.
3.
Pal, Sumanta K., Thomas Powles, Ravindran Kanesvaran, et al.. (2025). STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncology. 21(7). 787–794. 1 indexed citations
4.
Tannir, Nizar M., Xin Gao, Ritesh R. Kotecha, et al.. (2024). Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4513–4513. 4 indexed citations
5.
6.
Powles, Thomas, Mauricio Burotto, Bernard Escudier, et al.. (2024). Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 9(5). 102994–102994. 31 indexed citations
7.
Suárez, Cristina, et al.. (2023). Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors. SHILAP Revista de lepidopterología. 11(3). 46–46. 8 indexed citations
8.
Morales‐Barrera, Rafael, Guillermo Villacampa, Teresa Bonfill, et al.. (2023). Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clinical & Translational Oncology. 25(12). 3556–3564. 1 indexed citations
9.
McDermott, David F., Jae‐Lyun Lee, Marek Ziobro, et al.. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1029–1039. 183 indexed citations breakdown →
10.
Razak, Albiruni R. Abdul, Sebastian Bauer, Cristina Suárez, et al.. (2021). Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical Cancer Research. 28(6). 1087–1097. 43 indexed citations
11.
12.
Suárez, Cristina, et al.. (2021). Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. Current Opinion in Urology. 31(3). 242–248. 3 indexed citations
13.
Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526. 1 indexed citations
14.
Procopio, Giuseppe, Paul Hamberg, Pierre Bigot, et al.. (2020). 730P Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe. Annals of Oncology. 31. S571–S571. 1 indexed citations
15.
Szabados, Bernadett, Alejo Rodríguez‐Vida, Ignacio Durán, et al.. (2020). 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Annals of Oncology. 31. S1319–S1319. 3 indexed citations
16.
McGregor, Bradley A., Neeraj Agarwal, Cristina Suárez, et al.. (2020). 709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. Annals of Oncology. 31. S558–S558. 10 indexed citations
17.
18.
Carles, Joan, Enrique Gallardo, Montserrat Domènech, et al.. (2018). Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 103(2). 344–352. 5 indexed citations
19.
Pelegrín, Iván, Cristina Suárez, Alba Ribera, et al.. (2014). Listeria monocytogenes meningoencephalitis in adults: analysis of factors related to unfavourable outcome. Infection. 42(5). 817–827. 43 indexed citations
20.
Suárez, Cristina, Carmen Peña, Laura Gavaldà, et al.. (2010). Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. International Journal of Infectious Diseases. 14. e73–e78. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Baldwin Breakdown of academic impact, for papers by Antonello Di Paolo Breakdown of academic impact, for papers by Sunil Krishnan Breakdown of academic impact, for papers by Jean‐Paul Sculier Breakdown of academic impact, for papers by Judith E. Karp Breakdown of academic impact, for papers by Christopher J. Burns Breakdown of academic impact, for papers by Jos G. W. Kosterink Breakdown of academic impact, for papers by Kyong Hwa Park Breakdown of academic impact, for papers by David J. Kuter Breakdown of academic impact, for papers by Dorothea Nagel
Rankless by CCL
2026